Marlborough, Mass.-based Boston Scientific’s portfolio includes four MRI-conditional, Bluetooth-enabled implantable pulse generators (IPGs) and offers expanded personalization, rechargeable and non-rechargeable options and access to waveforms covering multiple areas of pain, according to a news release.
SCS therapies relieve pain through the delivery of mild electric current pulses to the spinal cord, interrupting pain signals to the brain. Boston Scientific’s WaveWriter Alpha systems garnered CE Mark approval with indications for managing chronic intractable pain and peripheral nerve stimulation of the trunk for pain management.
The system is touted as the only SCS portfolio with the ability to layer paraesthesia and paraesthesia-free options simultaneously, supporting up to 32 contacts targeting specific nerves along the spinal cord. The Bluetooth capabilities allow fast programming to be done while keeping 10 feet of distance between the programmer and the patient.
“The launch of the WaveWriter Alpha SCS systems in Europe represent a significant step forward in the treatment of chronic pain,” Boston Scientific senior VP & president of neuromodulation Maulik Nanavaty said in the release. “By unifying our portfolio of SCS devices and offering the latest therapy advances, we remain committed to advancing meaningful innovation, providing both physicians and patients access to the full benefits of our entire portfolio of devices.”